Concurrent Improvement in Scalp Hair and Eyebrow or Eyelash Regrowth in Patients With Severe Alopecia Areata Treated With Baricitinib

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

This study aimed to describe the distribution of eyebrow and eyelash hair loss in patients with varying severities of scalp hair loss from alopecia areata but does not report results.

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

In this study, trichoscopic examination found distinct hair characteristics for diagnosing eyebrow loss: alopecia areata is marked by features like exclamation mark hairs, while frontal fibrosing alopecia shows dystrophic hairs and distinctive regrowth patterns.

This study found that among patients with eyelash alopecia areata, 40% experienced complete regrowth of lashes, with a mean time to regrowth of 28 months.